The main event since our last update is the conclusion of the rights issue in April. In the same month, Qlife managed to raise the coverage to 100% through a top guarantee, which demonstrates good negotiating skills. However, the dilution from the issue is severe and the subscription rate of 31% was below average. Costs and investments have been reduced considerably in Q1, which is a positive development, and we expect them to fall furthert. As the company is launching its new product on the market, sales is starting slow at SEK0.1m in Q1.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/